Hossain, S., Sperling, A., Laubach, J., Miller, S., Vianna, P., Simpson, E., Chuma, M., Fink, B., Geberth, S., Magnavita, E., Khouri, J., Hoffman, J., Kaufman, J., Sanchorawala, V., Comenzo, R., Bianchi, G. (2025). A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results. Blood. https://doi.org/10.1182/blood-2025-5808